title: Promising new developments in cervical cancer.
abstract: Mary McCormack* speaks to Francesca Lake, Managing Commissioning Editor: Dr McCormack qualified as a doctor from Guy's and St Thomas's Hospital (London, UK) in 1993. She has worked in a variety of London cancer centers and was appointed as a consultant at University College London Hospitals (London, UK) in 2002. She is a clinical oncologist, offering chemotherapy and radiotherapy for gynecological and breast cancers. She is a member of the National Cancer Research Institute Gynecological Clinical Studies Group and the Gynecologic Cancer InterGroup, and is a major contributor to national and international clinical trials. She is also a medical advisor to Jo's Trust and a founding member of Debbie Fund, a University College London-based charity dedicated to raising funds for cervical cancer research.
authors.forename: Mary
authors.initials: M
authors.lastname: McCormack
authors.forename: Francesca
authors.initials: F
authors.lastname: Lake
mesh_terms: D005260:Female; D049674:History, 21st Century; D006801:Humans; D007494:Ireland; D008131:London; D018787:Radiation Oncology; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
keywords: INTERLACE; bevacizumab; cervical cancer; relapsed disease; research